Compare · ABT vs CDMO
ABT vs CDMO
Side-by-side comparison of Abbott Laboratories (ABT) and Avid Bioservices Inc. (CDMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and CDMO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $186.10B.
- ABT has hit the wire 9 times in the past 4 weeks while CDMO has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 9 for CDMO).
- Company
- Abbott Laboratories
- Avid Bioservices Inc.
- Price
- -
- -
- Market cap
- $186.10B
- -
- 1M return
- +3.63%
- -
- 1Y return
- -16.55%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 9
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Avid Bioservices Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Leadership Update
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Latest CDMO
- SEC Form 15-12G filed by Avid Bioservices Inc.
- Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
- V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operations Officer Richieri Richard A. returned 58,320 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Mackey Catherine J returned 43,379 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Kwietniak Matthew R. returned 50,796 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Hart Daniel R returned 112,735 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Hancock Richard B returned 124,191 shares to the company, closing all direct ownership in the company (SEC Form 4)